贞芪扶正胶囊配合化疗治疗晚期恶性肿瘤临床观察  

Clinical Observation of the Treatment of Advanced Cancer with Zhenqi Fuzheng Capsules in the Combination of Chemotherapy

作　　者：刘素勤[1] 孙亮新[1] 班丽英[1] 周涛[1] 

机构地区：[1]大连医科大学附属第一医院肿瘤科,辽宁大连116011

出　　处：《药物流行病学杂志》2006年第1期5-7,共3页Chinese Journal of Pharmacoepidemiology

摘　　要：目的:观察贞芪扶正胶囊配合化疗治疗晚期恶性肿瘤的疗效、不良反应、KPS评分及细胞免疫功能变化。方法:观察组患者100例,予贞芪扶正胶囊4粒,bid,po,于化疗前3 d开始至化疗2周期结束后7 d为1疗程; 对照组50例只给予化疗。观察疗效、毒副反应、KPS评分及细胞免疫功能变化。结果:两组化疗疗效无差异;观察组出现WBC减少少于对照组(61．0％vs 78．0％),化疗后KPS评分上升,CD4／CD8比值、NK阳性细胞百分率化疗后提高,差异显著(P<0．05)。结论:贞芪扶正胶囊配合化疗治疗晚期恶性肿瘤,WBC减少发生率低,可提高患者 KPS评分及细胞免疫功能,宜作为化疗的常规辅助中药用药。Objective： To evaluate the clinical efficacy, side effect, KPS scale and cytoimmunity function of Zhenqi Fuzheng capsules in the combination of chemotherapy in the treatment of advanced cancer. Method： 100 patients received Zhenqi Fuzheng capsules 4#, bid, po and chemotherapy for 2 courses. Fifty patients received chemotherapy as control group. Result： The overall response rates were 38.0% vs 34.0%, and the occurrence of leucopenia was 61.0% vs 78.0% （P 〈 0.05 ）, the improvement of KPS scale and both CD4/CDs and NK ratio was observed in Zhenqi Fuzheng capsules group （ P 〈 0.05 ）. Conclusion： Zhenqi Fuzheng capsules can decrease the occurrence of leucopenia and improve the KPS scale and cytoimmunity function in the period of chemotherapy.

关 键 词：贞芪扶正胶囊 行为状态评分 细胞免疫 化学治疗 肿瘤 恶性 

分 类 号：R734.2[医药卫生—肿瘤]